Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

TriPath Expanded Pap Labeling Data Claim Closes Gap With Cytyc

This article was originally published in The Gray Sheet

Executive Summary

TriPath expects narrower price differences between its SurePath and Cytyc's ThinPrep Pap test alternative over the long-term after receiving FDA sign-off on labeling that puts the tests on par for efficacy
Advertisement

Related Content

TriPath’s FocalPoint
TriPath’s FocalPoint
Patent Suit Or Smear Campaign? Automated Pap Firms Raise Legal Stakes
Patent Suit Or Smear Campaign? Automated Pap Firms Raise Legal Stakes
Inamed Performance Enhanced By Tech Assessment: Shares Up 38% In May
Inamed Performance Enhanced By Tech Assessment: Shares Up 38% In May
International News In Brief
International News In Brief
Digene DNA Pap Approval Anticipation Boosts Stock 45% In February
Advertisement
UsernamePublicRestriction

Register

MT018380

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel